Sivan Bercovici

Biography
Sivan is a recognized innovator and entrepreneur in artificial intelligence who has dedicated two decades to pioneering the development of complex computational and data platforms. His key contributions include the development of novel machine-learning models tackling significant challenges in human disease. At Karius, he spearheaded the development of the foundational computational platform underlying the Karius Test, elevated the biomarker discovery program, and was central to forming and nurturing key strategic partnerships, furthering the companys impact in the medical field. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode, where he led the development of the analytical platform and validation of several clinical assays across oncology and rare diseases. He holds a Ph.D. in Computer Science from the Technion Israel Institute of Technology, and continued to Stanfords Artificial Intelligence Lab to pursue his post-doctoral research.

---

Talk
Microbial Cell-Free DNA Unlocks Novel Biomarkers
Microbial cell-free DNA, discovered over a decade ago, now powers AI-driven liquid biopsy diagnostics for infectious diseases. The Karius Test, built on this platform, has supported 80,000+ cases across more than 500 hospitals. Its reach extends to autoimmune disease and cancer, showcasing the technologys versatility for novel liquid biopsy applications.

Clinical & Research Tools Showcase:
Karius
Karius, a biotech innovator, has been pioneering microbial cell-free DNA and AI-driven analysis for liquid biopsy diagnostics for infectious diseases for over a decade. The plasma-based Karius Test enables minimally invasive, rapid detection of pathogens and other disease biomarkers.